Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd operates as a pharmaceutical enterprise, focusing on the research, development, manufacturing, and commercialization of traditional Chinese medicines, health supplements, and active pharmaceutical ingredients (APIs). Its extensive product line includes therapeutic remedies such as Yuanhu Analgesic dropping pills, Qiwei Wenyang capsules, Maxing cough capsules, Shuxinning tablets, Panax notoginseng pills, Anti-inflammatory and gallbladder tablets, Children's Qingfei cough tablets, Pediatric Qinggan tablets, Suanzaoren oil dropping pills, Xiaoshuan Tongluo tablets, Xiaoyanlidan tablets, Compound Danshen tablets, Astragalus Angelica capsules, and berberine tannin films. Beyond its core manufacturing, the company is actively involved in the cultivation, procurement, processing, and distribution of Chinese medicinal raw materials. Its operations further encompass project investment and management, alongside the import, sale, logistics, and export of pharmaceutical goods. Established in 2002, Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd is headquartered in Lanzhou, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI